SWITCH OF ANTIRETROVIRAL THERAPY BASED ON HIV RESISTANCE GENOTYPING

基于 HIV 耐药基因分型的抗逆转录病毒治疗转换

• 批准号: 7605169
• 负责人: ANDREW RICHARD ZOLOPA
• 金额: $ 1.9万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605169
• 关键词: Clinical; Computer Retrieval of Information on Scientific Projects Database; Funding; Genotype; Grant; Highly Active Antiretroviral Therapy; Individual; Institution; Judgment; Lamivudine; Measures; Patients; Randomized; Randomized Controlled Trials; Research; Research Personnel; Resistance; Resources; Selection for Treatments; Source; Treatment Protocols; United States National Institutes of Health; antiretroviral therapy; base; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In this randomized, controlled trial, HIV-infected patients who failed their High Active Antiretroviral Therapy HAART will be offered individual treatment selection based on best clinical judgment and genotypic HIV-RNA resistance analysis. Patients who meet entry criteria will be randomized to receive 3TC plus salvage regimen versus no 3TC with salvage regimen. HIV-RNA load will be measured frequently after initiation of the therapy to determine virologic response.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在这项随机对照试验中，将根据最佳临床判断和基因型HIV-RNA耐药性分析，为高效抗逆转录病毒疗法HAART失败的HIV感染患者提供个体化治疗选择。 符合入选标准的患者将随机接受3 TC加挽救治疗方案与不接受3 TC加挽救治疗方案。 治疗开始后，将经常测量HIV-RNA载量，以确定病毒学应答。